Therefore, the development of IGF1R-targeted therapies sparked much excitement, given impressive responses of heavily pre-treated Ewing sarcoma patients in early clinical trials and a broad molecular basis supporting IGF1R as a tumor-driving RTK in this sarcoma [20]. This evidence concerns the gene IGF1R and Ewing sarcoma.